US Patent

US8535714 — Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain

Method of Use · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects small volume oral transmucosal dosage forms of sufentanil citrate for the treatment of pain.

USPTO Abstract

Compositions, systems and methods for administration of small volume sufentanil drug dosage forms via the oral transmucosal route of a subject for treatment of pain.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1351`	—	sufentanil-citrate

Patent Metadata

Patent number: US8535714
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-05
Drug substance claim: No
Drug product claim: Yes
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.